BioVectra
Canada Updated 9 July 2026
BioVectra is an API and finished-dose manufacturer based in Canada. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 26 August 2022 as VAI.
2
registered plants
2 with an FDA FEI number
6
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 26 August 2022 VAI US FDA
- 17 February 2017 VAI US FDA
- 17 April 2015 VAI US FDA
- 8 August 2013 NAI US FDA
- 25 August 2010 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Canada, Canada | 3004063541 |
| Canada, Canada | 3015684350 |
What they file, and where
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| MINSA (CR) | 6 | None |
Comparing suppliers?
Choose your molecules and target markets. BioVectra comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 26 August 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability